Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
163.76%
RETURN ON EQUITY (ROE) AVG 3Y
281.78%
RETURN ON EQUITY (ROE) AVG 5Y
257.03%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Akanda Corp.
Market Cap
$61819.00
Return on Equity (ROE)
N/A
TTM Avg
163.76%
3Y Avg
281.78%
5Y Avg
257.03%
Market Cap
$570131.00
Return on Equity (ROE)
-66.26%
TTM Avg
77.79%
3Y Avg
-17.48%
5Y Avg
-22.53%
Market Cap
$707297.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
Market Cap
$787624.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
Market Cap
$878396.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$885939.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$888387.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$1.02M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$1.11M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akanda Corp. (AKAN) | $61819.00 | N/A | 163.76% | 281.78% | 257.03% |
| HCW Biologics Inc. (HCWB)vs › | $570131.00 | -66.26% | 77.79% | -17.48% | -22.53% |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | -255.88% | -273.58% | -200.54% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -57.87% | -222.45% | -164.72% | -135.78% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -11.85% | -6.20% | 47.36% | 47.36% |
ROE
N/A
ROA
-736.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 423.31% |
| 2024-12-31 | -95.78% |
| 2023-12-31 | 842.93% |
| 2022-12-31 | -43.34% |
| 2021-12-31 | 369.36% |
| 2020-12-31 | 45.72% |
| 2019-12-31 | 0.00% |
